natgillin/translations-raw huggingface dataset:
After a heart attack (myocardial infarction)
Po srčni kapi (miokardnem infarktu)
After a median follow up of 3 years, sitagliptin, when added to usual care, did not increase the risk of major adverse cardiovascular events or the risk of hospitalization for heart failure compared to usual care without sitagliptin in patients with type 2 diabetes (Table 3).
Po 3 letih spremljanja (mediana) sitagliptin pri bolnikih s sladkorno boleznijo tipa 2, dodan običajnemu zdravljenju, ni povečal tveganja za pomembne neželene srčno-žilne dogodke ali tveganje za hospitalizacijo zaradi srčnega popuščanja v primerjavi z bolniki, ki so prejemali običajno zdravljenje brez sitagliptina (preglednica 3).
After a median follow-up of 144 weeks, 25 % of subjects on the ZDV/3TC/ABC/EFV arm and 26 % on the ZDV/3TC/EFV arm were categorised as having virological failure.
Po povprečno 144 tednih spremljanja je bil virološki neuspeh opažen pri 25 % oseb, ki so prejemale ZDV/3TC/ABC/EFV, in 26 % oseb, ki so prejemale ZDV/3TC/EFV.
After a median observation time of 25 months from randomization, maintenance therapy with MabThera resulted in a clinically relevant and statistically significant improvement in the primary endpoint of investigator assessed progression-free survival (PFS) as compared to observation in patients with previously untreated follicular lymphoma (Table 4).
Po mediani 25 mesecev opazovanja od randomizacije je vzdrževalno zdravljenje z zdravilom MabThera pri bolnikih s predhodno nezdravljenimi folikularnimi limfomi klinično pomembno in statistično značilno izboljšalo primarni opazovani dogodek – preživetje brez napredovanja bolezni (progression free survival – PFS), kot ga je določil raziskovalec – v primerjavi z opazovano skupino (preglednica 4).
After a median observation time of 25 months from randomization, maintenance therapy with MabThera resulted in a clinically relevant and statistically significant improvement in the primary endpoint of investigator assessed progression-free survival (PFS) as compared to observation in patients with previously untreated follicular lymphoma (Table 5).
Po mediani časa opazovanja 25 mesecev od randomizacije je vzdrževalno zdravljenje z zdravilom MabThera pri bolnikih s predhodno nezdravljenimi folikularnimi limfomi klinično pomembno in statistično značilno izboljšalo primarni opazovani dogodek – preživetje brez napredovanja bolezni (progression free survival – PFS), kot ga je določil raziskovalec – v primerjavi z opazovano skupino (preglednica 5).
After a minimum of 5 seconds, pull the needle out of the skin while keeping the dose setting knob pressed down (3).
Po vsaj 5 sekundah izvlecite iglo iz kože in še vedno držite gumb za odmerek navzdol (3).
After a minimum of 60 months follow-up the cumulative rates for rash (14%), musculoskeletal pain (14%), headache (13%), fatigue (11%), nausea (10%), myalgia (7%), vomiting (5%), and muscle inflammation or spasms (5%) increased by  3%.
Po najmanj 60-mesečnem obdobju spremljanja so se kumulativni deleži kožnega izpuščaja (14%), mišično-skeletne bolečine (14%), glavobola (13%), utrujenosti (11%), navzee (10%), mialgije (7%), bruhanja (5%) in vnetja mišic ali mišičnih krčev (5%) povečali za  3%.
After a number of rounds of replication genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells have a high DNA damage load relative to normal cells.
Po številnih ponovitvah replikacije lahko genomska nestabilnost doseže nevzdržno raven in povzroči odmrtje rakave celice, ker imajo rakave celice v primerjavi z normalnimi veliko okvar DNA.
After a one-hour intravenous infusion, asparaginase activity was detected for at least 15 days after the first treatment with Oncaspar.
Po zdravljenju z 1-urno intravensko infuzijo so zaznali aktivnost asparaginaze še najmanj 15 dni po prvem zdravljenju z zdravilom Oncaspar.
After a primary vaccination with 2 doses of HEXAVAC (i.e.
Po uradnih priporočilih se mora pri primarnem cepljenju z 2 odmerkoma HEXAVAC-a (npr.
After a single 100 mg dose of isavuconazole was administered to 32 patients with mild (Child-Pugh Class A) hepatic insufficiency and 32 patients with moderate (Child-Pugh Class B) hepatic insufficiency (16 intravenous and 16 oral patients per Child-Pugh class), the least square mean systemic exposure (AUC) increased 64% in the Child-Pugh Class A group, and 84% in the Child-Pugh Class B group, relative to 32 age- and weight-matched healthy subjects with normal hepatic function.
Po tem, ko je 32 bolnikov z blago (Child-Pugh razred A) in 32 bolnikov z zmerno jetrno insuficienco (Child-Pugh razred B) prejelo enkratni 100 mg odmerek izavukonazola (16 intravensko in 16 peroralno pri vsakem razredu Child-Pugh) se je najniţja povprečna vrednost (po metodi najmanjših kvadratov) sistemske izpostavljenosti (AUC) povečala za 64 % v skupini razreda Child-Pugh A in za 84 % v skupini razreda Child-Pugh B v primerjavi z 32 zdravimi preiskovanci enake starosti in telesne mase z normalnim delovanjem jeter.
After a single 250 mg dose in subjects with severe renal impairment (CLcr <30 mL/min) not requiring peritoneal dialysis or haemodialysis, crizotinib AUC and Cmax increased by 79% and 34%, respectively, compared to those with normal renal function.
Po enkratnem 250 mg odmerku pri osebah s hudo okvaro ledvic (CLcr < 30 mL/min), ki ni zahtevala peritonealne dialize ali hemodialize, se je AUC krizotiniba v primerjavi z osebami z normalnim delovanjem ledvic povečala za 79 %, Cmax pa za 34 %.
After a single 800 mg oral dose of 14C-boceprevir, the most abundant circulating metabolites were a diasteriomeric mixture of ketone-reduced metabolites with a mean exposure approximately 4fold greater than that of boceprevir.
Po enkratnem peroralnem odmerku 800 mg 14C-boceprevirja je bilo v obtoku največ presnovkov, ki so bili mešanica diastereomer ketonskih reduciranih presnovkov, s približno 4krat večjo povprečno izpostavljenostjo, kot je izpostavljenost boceprevirju.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Po enkratnem odmerku s 14C označenega telmisartana odpade na glukuronid približno 11 % radioaktivnosti, izmerjene v plazmi.
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured radioactivity in plasma.
Po enkratnem odmerku s C14 označenega telmisartana odpade na glukuronid približno 11 % radioaktivnosti, izmerjene v plazmi.
After a single dose of [14C] sirolimus in healthy volunteers, the majority (91.1%) of radioactivity was recovered from the faeces, and only a minor amount (2.2%) was excreted in urine.
Po enkratnem odmerku s 14C označenega sirolimusa pri zdravih prostovoljcih so večino radioaktivnosti (91,1 %) izmerili v blatu in le manjšo količino (2,2 %) v urinu.
After a single dose of CE/bazedoxifene, baseline-adjusted total estrone (representing CE) is eliminated with a half-life of approximately 17 hours.
Po enkratnem odmerku CE/bazedoksifena je razpolovna doba izločanja skupnega estrona, prilagojenega glede na izhodiščno vrednost (ki predstavlja CE), približno 17 ur.
After a single dose of CE/bazedoxifene, bazedoxifene and baseline-adjusted total estrone were absorbed with a tmax of approximately 2 hours and 8.5 hours, respectively.
Po enkratnem odmerku CE/bazedoksifena je bila vrednost tmax za absorpcijo bazedoksifena približno 2 uri, za skupni estron, prilagojen glede na izhodiščno vrednost, pa 8,5 ur.
After a single dose, intracellular and serum activity of 2’5’OAS synthetase and serum concentrations of beta-2 microglobulin and neopterin increase within 24 hours, and start to decline within 2 days.
Po enkratnem odmerku se v 24 urah povečajo intracelularna in serumska aktivnost 2-5A sintetaze in serumske koncentracije beta-2 mikroglobulina ter neopterina in pričnejo upadati v 2 dneh.
After a single dose, the duration of analgesia was dose and clinical pain model dependent, and ranged from 6 to greater than 12 hours.
Po posamičnem odmerku je bilo trajanje analgezije odvisno od odmerka in modela klinične bolečine in je segalo od 6 do več kot 12 ur.
After a single IM injection with ZYPADHERA the slow dissolution of the olanzapine pamoate salt in muscle tissue begins immediately and provides a slow continuous release of olanzapine for more than four weeks.
Po enkratnem i.m. injiciranju zdravila ZYPADHERA se v mišičnem tkivu takoj začne počasno raztapljanje olanzapinijevega pamoata ter zagotavlja počasno, nenehno sproščanje olanzapina več kot štiri tedne.
After a single intravenous dose of 10 micrograms/kg [14C]-palonosetron, approximately 80 % of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40 % of the administered dose, as unchanged active substance.
Po enojnem intravenskem odmerku 10 mikrogramov/kg 14C - palonosetrona, se 80 % odmerka v 144 urah izloči v urinu, kjer je 40 % danega odmerka palonosetrona aktivna nespremenjena substanca.
After a single intravenous dose of 250 mg, the clearance was 8.2 L/h.
Po enkratnem intravenskem odmerku 250 mg je bil očistek 8,2 l/h.
After a single intravenous injection of 0.03 or 0.3 ml of SonoVue/kg (approximately 1 and 10 times the maximum clinical dose) to human volunteers, the sulphur hexafluoride was cleared rapidly.
Po enkratnem intravenskem injiciranju 0,03 ali 0,3 ml zdravila SonoVue/kg (približno 1 do 10 kratnik maksimalnega kliničnega odmerka) prostovoljcem, se je žveplov heksafluorid hitro izločil.
After a single IV administration, the total body clearance of teriflunomide is 30.5 ml/h.
Po enem i.v. dajanju je bil skupni telesni očistek teriflunomida 30,5 ml/h.
After a single oral administration of radiolabeled [14C]-ibrutinib in healthy subjects, approximately 90% of radioactivity was excreted within 168 hours, with the majority (80%) excreted in the faeces and < 10% accounted for in urine.
Pri zdravih osebah se je po peroralnem odmerjanju posameznega odmerka ibrutiniba, radioaktivno označenega s [14C], približno 90% radioaktivnosti izločilo v 168 urah, pri čemer se je večina (80%) izločila z blatom, < 10% pa z urinom.
After a single oral dose of 0.4 mg meloxicam/kg a Cmax value of 0.81 µg/ml was reached after 2 hours.
Po enkratnem peroralnem odmerku 0,4 mg meloksikama/kg je bila dosežena vrednost Cmax 0,81 µg/ml po 2 urah.
After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function.
Po enkratnem peroralnem odmerku 400 mg peroralne suspenzije posakonazola pri bolnikih z blago (razred A po Child-Pughu), zmerno (razred B po Child-Pughu) ali hudo okvaro jeter (razred C po Child-Pughu) (po šest bolnikov na skupino) je bila povprečna AUC od 1,3 - do 1,6- krat večja kot pri odgovarjajočih preiskovancih iz kontrolne skupine, ki so imeli normalno delovanje jeter.
After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function.
Po enkratnem peroralnem odmerku 400 mg peroralne suspenzije posakonazola pri bolnikih z blago (razred A po Child-Pughu), zmerno (razred B po Child-Pughu) ali hudo okvaro jeter (razred C po Child-Pughu) (po šest bolnikov na skupino) je bila povprečna AUC od 1,3 do 1,6- krat večja kot pri odgovarjajočih preiskovancih iz kontrolne skupine, ki so imeli normalno delovanje jeter.
After a single oral dose of 500 mg bosutinib with food, the mean elimination half-life was approximately 34 hours, and the mean clearance (Cl/F) was 197 + 57 L/h.
Po zaužitju enkratnega peroralnega 500 mg odmerka bosutiniba skupaj s hrano je povprečni razpolovni čas izločanja znašal 34 ur, povprečni očistek (Cl/F) pa je bil 197 ± 57 l/h.
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 μg/ml were reached after
Po enkratnem podkožnem odmerku meloksikama po 0,5 mg/kg je znašala C pri mladem govedu 2,1
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmaxvalues of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Po enkratnem subkutanem odmerku meloksikama po 0,5 mg/kg je znašala Cmax pri mladem govedu in kravah v obdobju laktacije 2,1 g/ml in 2,7 g/ml po 7,7 ure in 4 urah.
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmaxvalues of 2.1 μg/ml and 2.7 μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Po enkratnem podkožnem odmerku meloksikama po 0,5 mg/kg je znašala Cmax pri mladih govedih in kravah v obdobju laktacije 2,1 µg/ml in 2,7 µg/ml po 7,7 ure in 4 urah.
After a single subcutaneous dose of 1 to 10 µg/kg romiplostim in ITP patients, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2 to 3 week period and the response was variable among patients.
Pri bolnikih z ITP se je število trombocitov po posamičnem subkutanem odmerku od 1 do 10 µg/kg romiplostima v 2 do 3 tednih povečalo za 1,3- do 14,9-krat v primerjavi z izhodiščem, odziv pa se je med bolniki razlikoval.
After a single subcutaneous dose of 1 to 10 µg/kg romiplostim in ITP patients, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2 to 3 week period and the response was variable among patients.
Pri bolnikih z ITP se je število trombocitov po posamičnem subkutanem odmerku od 1 do 10 µg/kg romiplostima v 2 do 3 tednih povečalo za 1,3-do 14,9-krat v primerjavi z izhodiščem, odziv pa se je med bolniki razlikoval.
After a single subcutaneous dose of 25 mg Enbrel, the average maximum serum concentration observed in healthy volunteers was 1.65  0.66 g/ml, and the area under the curve was 235  96.6 ghr/ml
Po enkratnem subkutanem odmerku 25 mg zdravila Enbrel je bila povprečna največja koncentracija zdravila v serumu pri zdravih prostovoljcih 1,65  0,66 g/ml, površina pod krivuljo pa 235  96,6 g·h/ml.
After a single subcutaneous dose of 25 mg Enbrel, the average maximum serum concentration observed in healthy volunteers was 1.65  0.66 g/ml, and the area under the curve was 235  96.6 ghr/ml.
Po enkratnem subkutanem odmerku 25 mg zdravila Enbrel je bila povprečna največja koncentracija zdravila v serumu pri zdravih prostovoljcih 1,65  0,66 g/ml, površina pod krivuljo pa 235  96,6 g·h/ml.
After a single subcutaneous injection of 6 mg lipegfilgrastim during the fourth cycle, the maximum blood concentrations were lower than observed in the first cycle (mean values 77 and 111 ng/ml) and were reached after median tmax of 8 hours.
Po enem subkutanem injiciranju 6 mg lipegfilgrastima v četrtem ciklu so bile največje koncentracije v krvi nižje kot v prvem ciklu (povprečni vrednosti 77 in 111 ng/ml), doseženi pa sta bili po 8 urnem medianem tmax.
After a single subcutaneous injection of Elonva, the maximum serum concentration of corifollitropin alfa is 4.24 ng/mL (2.49-7.21 ng/mL1) and is reached 44 hours (35-57 hours1) postdose.
Po enkratni subkutani injekciji zdravila Elonva je največja serumska koncentracija korifolitropina alfa 4,24 ng/ml (2,49-7,21 ng/ml1) in je dosežena 44 ur (od 35 do 57 ur1) po odmerku.
After a single topical application of the veterinary medicinal product, the actives were detected at various regions of the cat’s body, including the caudal region, within the first days of application, indicating distribution/movement from the site of application (between the head and shoulder blades) across the body of the animal.
Po enkratnem nanosu zdravila na eno mesto na koži je v prvih dneh po nanosu učinkovini mogoče ugotoviti na različnih delih telesa mačke, vključno s kavdalnim delom telesa, kar kaže na distribucijo/migracijo zdravila z mesta nanosa (med glavo in lopaticama) po vsem telesu.
After a single-dose of approximately 0.75 mg intravenous palonosetron, the total body clearance of palonosetron in healthy subjects was 160 ± 35 ml/h/kg (mean
Po enkratnem odmerku približno 0,75 mg intravenskega palonosetrona je bil celotni telesni očistek palonosterona pri zdravih preiskovancih 160
After a tenfold overdose in both dog and cat the following clinical signs have been observed :
Po desetkratnem predoziranju so se pri psih kot tudi pri mačkah pojavila naslednja klinična znamenja:
After a thorough assessment of the available data, there appears to be reasonable support for the possibility of a causal relationship between Xolair and systemic lupus erythematosus.
Po temeljiti presoji razpoložljivih podatkov se zdi možnost, da je zdravilo Xolair vzročno povezano s sistemskim eritematoznim lupusom, dovolj utemeljena.
After a treatment period of 7-10 days, the condition of the dog should be re- evaluated in order to establish the need for continuation of treatment.
Po 7-10 dnevnem zdravljenju se psa ponovno pregleda, da se ugotovi ali je potrebno nadaljevati z zdravljenjem.
After a year, the patients who took Daxas had an average increase of 40 ml while those given placebo had an average decrease of 9 ml.
Po enem letu so imeli bolniki, ki so jemali zdravilo Daxas, v povprečju 40 ml večjo vrednost FEV1, medtem ko se je pri tistih, ki so prejemali placebo, ta vrednost zmanjšala za 9 ml.
After a year, there was a decrease of about two-thirds in the number of MS attacks in Tysabri-treated patients, in comparison with the patients who received placebo.
Po enem letu se je pri bolnikih, zdravljenih z zdravilom Tysabri, število napadov multiple skleroze v primerjavi z bolniki, ki so prejemali placebo, zmanjšalo za približno dve tretjini.
After about 7 years, a 28% median reduction in IgG levels was observed, with 1.6% of subjects experiencing a decrease in IgG levels to below 400 mg/dl.
Po približno sedmih letih so opazili 28-odstotno mediano znižanje koncentracije IgG; 1,6 % osebam se je koncentracija IgG znižala pod 400 mg/dl.
After absorption, 66% of pravastatin undergoes a first-pass extraction through the liver, which is the primary site of its action and the primary site of cholesterol synthesis and clearance of LDL- cholesterol.
Po absorpciji se 66 % pravastatina izloči s prvim prehodom skozi jetra, ki so primarno mesto njegovega delovanja ter primarno mesto za sintezo holesterola in čiščenje holesterola LDL.
After accidental ingestion of the highest recommended dose, vomiting, salivation and diarrhoea may occur, however these should resolve without treatment.
Po nenamernem zaužitju najvišjega priporočenega odmerka, se lahko pojavijo bruhanje, slinjenje in driska, ki pa izginejo brez zdravljenja.
After accidental ingestion of the product, transient reactions such as salivation, abnormal faeces and emesis may occur, however these should resolve without treatment within 4 hours.
Po nenamernem zaužitju, se lahko pojavijo prehodne reakcije kot so slinjenje, neobičajno blato in bruhanje, ki pa izginejo brez zdravljenja v 4 urah.
After accidental oral ingestion or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may occur in very rare cases.
Pri nenamernem zaužitju zdravila ali pri prekomernem odmerjanju se lahko v zelo redkih primerih pojavijo nevrološki znaki ( večina jih je prehodnih) kot so ataksija, generaliziran tremor, očesni znaki (razširjene zenice, slab pupilarni refleks, očesni drget), nenormalno dihanje, slinjenje in bruhanje.
After accounting for body weight differences, no clinically significant differences in the pharmacokinetic properties of canakinumab were observed between CAPS and SJIA patients.
Ob upoštevanju razlike v telesni masi med bolniki s CAPS in bolniki s SJIA, niso med navedenimi bolniki opažali nobenih razlik v farmakokinetičnih lastnostih kanakinumaba.
After activation: Do not store above 30°C
Po aktiviranju: Shranjujte pri temperaturi do 30 °C.
After activation: use within 12 hours
Po aktiviranju: uporabite v 12 urah.
After adding the solvent, shake the vial moderately for a minimum of 30 seconds until a uniform suspension is formed.
Po dodajanju vehikla vialo zmerno stresajte najmanj 30 sekund, dokler ne nastane enotna suspenzija.
After adjusting for baseline characteristics in a secondary analysis, the HR for the primary composite endpoint was 0.88; 95% CI: 0.79, 0.97.
Po korekciji za izhodiščne značilnosti v sekundarni analizi je bilo razmerje ogroženosti za primarni sestavljeni opazovani dogodek 0,88, 95% interval zaupanja: 0,79, 0,97.
After adjusting for differences in creatinine clearance and body weight, elderly subjects had a 12.5% higher AUC than young subjects.The population pharmacokinetic analysis covering patients in the age range 16-
Po prilagoditvi glede na razlike kreatininskega očistka in telesne mase so bile pri starostnikih vrednosti AUC za 12,5% večje od vrednosti pri mlajših osebah.
After administering half of the dose in one nostril, administer the other half of the dose in the other nostril immediately or shortly thereafter.
Kmalu ali takoj po aplikaciji polovice odmerka v eno nosnico aplicirajte drugo polovico v drugo nosnico.
After administering half of the dose in one nostril, administer the other half of the dose in the other nostril immediately or shortly thereafter.
Kmalu ali takoj po aplikaciji polovice odmerka v eno nosnico dajte drugo polovico v drugo nosnico.
After administration of 14C-posaconazole as oral suspension, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose).
14C-posakonazola v obliki peroralne suspenzije se je radioaktivnost pojavila predvsem v blatu (77 % radioaktivno označenega odmerka); glavni del tega je bila matična spojina (66 % radioaktivno označenega odmerka).
After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose).
Po dajanju 14C-posakonazola so radioaktivnost ugotovili predvsem v blatu (77 % radioaktivno označenega odmerka), glavna komponenta pa je bila matična spojina (66 % radioaktivno označenega odmerka).
After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose).
Po uporabi 14C-posakonazola se je radioaktivnost pojavila predvsem v blatu (77 % radioaktivno označenega odmerka); glavni del tega je bila matična spojina (66 % radioaktivno označenega odmerka).
After administration of 30 mg/m2 doses, steady-state conditions are reached for tegafur, gimeracil, and oteracil at the latest by Day 8.
Po uporabi odmerkov 30 mg/m2 se vzpostavi stanje dinamičnega ravnovesja za tegafur, gimeracil in oteracil, in sicer najpozneje na 8. dan.
After administration of a 50 mg
Po uporabi odmerka 50 mg
After administration of a 50 mg [14C]-dapagliflozin dose, 96% was recovered, 75% in urine and 21% in feces.
Po dajanju 50-mg odmerka [14C]-dapagliflozina se ga je 96 % izločilo, in sicer 75 % v urinu in 21 % v blatu.
After administration of a double dose, local reactions may increase slightly. (see section 4.6)..
Po dajanju dvojnega odmerka se lahko nekoliko povečajo lokalne reakcije (glejte poglavje 4.6).
After administration of a radiolabeled 14C-etravirine dose, 93.7% and 1.2% of the administered dose of 14C-etravirine could be retrieved in faeces and urine, respectively.
Po dajanju odmerka radioaktivno označenega etravirina-C14 so v blatu našli 93,7% prejetega odmerka etravirina-C14, v seču pa 1,2%.